ELUT
Elutia Inc
$
0.590
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.6313
Open
0.601
VWAP
0.60
Vol
225.59K
Mkt Cap
25.20M
Low
0.580
Amount
135.24K
EV/EBITDA(TTM)
--
Total Shares
27.52M
EV
46.58M
EV/OCF(TTM)
--
P/S(TTM)
1.07
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
3.60M
-42.52%
-0.120
-47.83%
3.35M
-44.44%
-0.120
-42.86%
3.50M
-35.99%
-0.120
-53.85%
Estimates Revision
The market is revising Downward the revenue expectations for Elutia Inc. (ELUT) for FY2025, with the revenue forecasts being adjusted by -31% over the past three months. During the same period, the stock price has changed by -71.77%.
Revenue Estimates for FY2025
Revise Downward
-31%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-34.56%
In Past 3 Month
Stock Price
Go Down
-71.77%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast ELUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELUT is 3.50 USD with a low forecast of 2.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.590
Low
2.00
Averages
3.50
High
5.00
Current: 0.590
Low
2.00
Averages
3.50
High
5.00
Cantor Fitzgerald
Overweight -> Overweight
downgrade
$7 -> $5
2025-08-18
Reason
Cantor Fitzgerald
Price Target
$7 -> $5
2025-08-18
downgrade
Overweight -> Overweight
Reason
Cantor Fitzgerald lowered the firm's price target on Elutia to $5 from $7 and keeps an Overweight rating on the shares.
Lake Street
Buy
downgrade
$10 -> $8
2025-05-09
Reason
Lake Street
Price Target
$10 -> $8
2025-05-09
downgrade
Buy
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$8
2025-03-07
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$8
2025-03-07
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Elutia Inc (ELUT.O) is -1.22, compared to its 5-year average forward P/E of -2.93. For a more detailed relative valuation and DCF analysis to assess Elutia Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.93
Current PE
-1.22
Overvalued PE
-1.29
Undervalued PE
-4.57
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-2.19
Undervalued EV/EBITDA
-10.17
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.30
Current PS
0.00
Overvalued PS
3.33
Undervalued PS
1.26
Financials
Annual
Quarterly
FY2025Q3
YoY :
-43.89%
3.32M
Total Revenue
FY2025Q3
YoY :
-21.49%
-4.36M
Operating Profit
FY2025Q3
YoY :
-129.78%
-383.00K
Net Income after Tax
FY2025Q3
YoY :
-366.67%
-0.08
EPS - Diluted
FY2025Q3
YoY :
-11.50%
-3.52M
Free Cash Flow
FY2025Q3
YoY :
+20.46%
55.76
Gross Profit Margin - %
FY2025Q3
YoY :
+184.48%
-230.29
FCF Margin - %
FY2025Q3
YoY :
-153.08%
-11.53
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
21.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
2.1M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
2
21.6K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
2.1M
USD
Months
ELUT News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
17:20:18
Elutia announces Q3 earnings per share of 19 cents, compared to a loss of 33 cents last year.
2025-10-10 (ET)
2025-10-10
08:02:08
Elutia names Guido Neels to its board of directors
2025-10-01 (ET)
2025-10-01
08:43:56
Elutia completes $88M sale of BioEnvelope division to Boston Scientific
Sign Up For More Events
Sign Up For More Events
News
5.0
10-10NewsfilterElutia Welcomes Experienced MedTech Leader Guido J. Neels to Its Board of Directors
4.0
10-01TipRanksAnalysts' Picks: The 3 Most Trending Stocks as of October 1, 2025
8.5
09-17NASDAQ.COMBiotech Stocks Surge After Hours Due to Trial Advancements, Funding Developments, and Anticipated Milestones
Sign Up For More News
People Also Watch
FAQ
What is Elutia Inc (ELUT) stock price today?
The current price of ELUT is 0.5901 USD — it has decreased -4.07 % in the last trading day.
What is Elutia Inc (ELUT)'s business?
What is the price predicton of ELUT Stock?
What is Elutia Inc (ELUT)'s revenue for the last quarter?
What is Elutia Inc (ELUT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Elutia Inc (ELUT)'s fundamentals?
How many employees does Elutia Inc (ELUT). have?